Vanda Pharmaceuticals Inc.
VNDADrugs in Pipeline
21
Phase 3 Programs
13
Upcoming Catalysts
6
Next Catalyst
Jul 30, 2026
5wMarket Overview
Stock performance and key metrics
7 upcoming, 3 past
Ponesimod
Moderate-to-severe Chronic Plaque Psoriasis
iloperidone
Schizophrenia
Open Label Tradipitant
Idiopathic Gastroparesis
Tradipitant
Motion Sickness
Imsidolimab high dose
Generalized Pustular Psoriasis
VQW-765
Performance Anxiety
20 mg VEC-162
Insomnia
Tasimelteon Oral Suspension
Insomnia Disorder
Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension
Autism Spectrum Disorder
Ziprasidone
Schizophrenia
VEC-162 20 mg
Primary Insomnia
Tasimelteon
Sleep Wake Disorders
Milsaperidone
Major Depressive Disorder (MDD)
VSJ-110
Dry Eye
Imsidolimab
Acne Vulgaris
Trichostatin A
Onychomycosis of Toenail
VSF-173
Excessive Somnolence
VLY-686 (Tradipitant)
Gastroparesis
VCA-894A
Charcot Marie Tooth Disease (CMT)
VLY-686
Treatment-resistant Pruritus Associated With Atopic Dermatitis
VEC-162
Circadian Rhythm Sleep Disorders
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ponesimod | Phase 3 | Moderate-to-severe Chronic Plaque Psoriasis | - | - |
iloperidone | Phase 3 | Schizophrenia | - | - |
Open Label Tradipitant | Phase 3 | Idiopathic Gastroparesis | - | - |
Tradipitant | Phase 3 | Motion Sickness | - | - |
Imsidolimab high dose | Phase 3 | Generalized Pustular Psoriasis | - | - |
VQW-765 | Phase 3 | Performance Anxiety | - | - |
20 mg VEC-162 | Phase 3 | Insomnia | - | - |
Tasimelteon Oral Suspension | Phase 3 | Insomnia Disorder | - | - |
Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension | Phase 3 | Autism Spectrum Disorder | - | - |
Ziprasidone | Phase 3 | Schizophrenia | - | - |
VEC-162 20 mg | Phase 3 | Primary Insomnia | - | - |
Tasimelteon | Phase 3 | Sleep Wake Disorders | - | - |
Milsaperidone | Phase 3 | Major Depressive Disorder (MDD) | - | - |
VSJ-110 | Phase 2 | Dry Eye | - | - |
Imsidolimab | Phase 2 | Acne Vulgaris | - | - |
Trichostatin A | Phase 2 | Onychomycosis of Toenail | - | - |
VSF-173 | Phase 2 | Excessive Somnolence | - | - |
VLY-686 (Tradipitant) | Phase 2 | Gastroparesis | - | - |
VCA-894A | Phase 2 | Charcot Marie Tooth Disease (CMT) | - | - |
VLY-686 | Phase 2 | Treatment-resistant Pruritus Associated With Atopic Dermatitis | - | - |
VEC-162 | Phase 2 | Circadian Rhythm Sleep Disorders | - | - |